Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Watson

- PMLiVE

Pfizer’s breast cancer drug palbociclib extends survival

Positive trial results for oncology treatment

- PMLiVE

Pfizer appoints comms head in Spain

Monica Piñuela is promoted

- PMLiVE

Merck KGaA and Pfizer collaborate on lupus

Companies team up with academics to research treatments for autoimmune disorder

- PMLiVE

Pfizer gains ground in cholesterol antibody chase

 Reports positive phase 2b data for its PCSK9 blocker

- PMLiVE

Pfizer says Xalkori tops chemo as first line therapy

Superior progression free survival for lung cancer patients

- PMLiVE

Pfizer’s meningitis vaccine ‘a breakthrough’

FDA to speed up review process for bivalent rLP2086

Bristol-Myers Squibb (BMS) building

BMS strikes $350m deal to boost its immuno-oncology pipeline

Will collaborate with US biotech Five Prime Therapeutics

- PMLiVE

FDA approves new indication for Pfizer/BMS’ Eliquis

Oral anticoagulant gains US approval for deep vein thrombosis use

- PMLiVE

Pfizer 2014 guidance threatened by Celebrex competition

Court overturns key patent for osteoarthritis drug

- PMLiVE

Pfizer still number one – just

The PMLiVE Top Pharma List is updated with a ranking of the 25 biggest companies in the industry

- PMLiVE

Pfizer recalls depression drug in US

Wrong medicine found in bottle of Effexor XR

- PMLiVE

NICE relents and backs Pfizer’s Inlyta

Recommends drug to treat advanced kidney cancer on NHS in England

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links